Ítem
Acceso Abierto

Microorganismos y perfiles de resistencia en aislamientos de infecciones quirúrgicas intraabdominales en un Hospital de Bogotá – Colombia, 2017 – 2018

Mostrar el registro sencillo de la publicación
dc.contributor.advisorIsaza Restrepo, Andrés
dc.contributor.advisorBuitrago, Daniel Felipe
dc.creatorGuerrero Vergel, Alvaro Felipe
dc.creator.degreeEspecialista en Cirugía Generalspa
dc.creator.degreetypeFull timespa
dc.date.accessioned2019-01-18T19:05:30Z
dc.date.available2019-01-18T19:05:30Z
dc.date.created2019-01-16
dc.date.issued2019
dc.descriptionEl conocimiento de las tasas regionales/locales de resistencia debe ser siempre un componente esencial del proceso de toma de decisiones clínicas cuando se decide el tratamiento empírico de la infección. Se encontraron microorganismos y perfiles de resistencia con características muy similares a los reportados en el resto del mundo, como microorganismos catalogados como ESKAPE principalmente relacionados con infecciones de origen intrahospitalario y con perfiles de resistencia que evidenciaban una baja resistencia respecto a los reportes referenciados.spa
dc.description.abstractKnowledge of regional/local rates of resistance should always be an essential component of the clinical decision-making process when deciding on the empirical treatment of an infection. Microorganisms and resistance profiles founded have similar characteristics to those reported in the rest of the world, such as microorganisms cataloged as ESKAPE, mainly related to infections of intrahospitalary origin and resistance profiles showed a low resistance with respect to the referenced reports.spa
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_18887
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/18887
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Medicinaspa
dc.publisher.programEspecialización en Cirugía Generalspa
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationWatkins RR, Bonomo RA. Overview: Global and Local Impact of Antibiotic Resistance. Vol. 30, Infectious Disease Clinics of North America. 2016. p. 313–22.spa
dc.source.bibliographicCitationRoca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: Science for intervention. Vol. 6, New Microbes and New Infections. 2015. p. 22–9.spa
dc.source.bibliographicCitationWho. ORIGINAL : ENGLISH WHO Global Strategy for Containment of Antimicrobial Strategy for Containment of Antimicrobial Resistance. World Health [Internet]. 2001;WHO/CDS/CS:105. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:WHO+Global+Strategy+for+Containment+of+Antimicrobial+Resistance#0spa
dc.source.bibliographicCitationLuepke KH, Suda KJ, Boucher H, Russo RL, Bonney MW, Hunt TD, et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37(1):71–84.spa
dc.source.bibliographicCitationAlvarez CA, Yomayusa N, Leal AL, Moreno J, Mendez-Alvarez S, Ibañez M, et al. Nosocomial infections caused by community-associated methicillin-resistant Staphylococcus aureus in Colombia. Am J Infect Control. 2010;38(4):315–8.spa
dc.source.bibliographicCitationAlvarez C, Cortes J, Arango A, Correa C, Leal A. [Anti-microbial resistance in intensive care units in Bogota, Colombia, 2001-2003]. Rev Salud Publica [Internet]. 2006;8 Suppl 1:86–101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16925124spa
dc.source.bibliographicCitationLeal AL, Eslava-Schmalbach J, Alvarez C, Buitrago G, Méndez M, Grupo para el Control de la Resistencia Bacteriana en Bogotá. [Endemic tendencies and bacterial resistance markers in third-level hospitals in Bogotá, Colombia]. Rev salud pública (Bogotá, Colomb [Internet]. 2006;8 Suppl 1:59–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16925122spa
dc.source.bibliographicCitationVillegas M V, Correa A, Perez F, Miranda MC, Zuluaga T, Quinn JP, et al. Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagnostic Microbiol Infect Dis. 2004;49:217–22.spa
dc.source.bibliographicCitationMcGowan JE. Economic impact of antimicrobial resistance. Emerg Infect Dis. 2001;7(2):286–92.spa
dc.source.bibliographicCitationEvans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35(1):89–95.spa
dc.source.bibliographicCitationCoast J, Smith RD. Antimicrobial resistance: cost and containment. Expert Rev Anti Infect Ther [Internet]. 2003;1(2):241–51. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15482119spa
dc.source.bibliographicCitationMazuski JE, Solomkin JS. Intra-Abdominal Infections. Vol. 89, Surgical Clinics of North America. 2009. p. 421–37.spa
dc.source.bibliographicCitationDavies J, Davies D. Origins and Evolution of Antibiotic Resistance. Microbiol Mol Biol Rev [Internet]. 2010;74(3):417–33. Available from: http://mmbr.asm.org/cgi/doi/10.1128/MMBR.00016-10spa
dc.source.bibliographicCitationFonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic resistance in Mycobacterium tuberculosis. Vol. 32, International Journal of Infectious Diseases. 2015. p. 94–100.spa
dc.source.bibliographicCitationDeutschendorf C, Goldani LZ, Pires dos Santos R. Previous use of quinolones: A surrogate marker for first line anti-tuberculosis drugs resistance in HIV-infected patients? Brazilian J Infect Dis. 2012;16(2):142–5.spa
dc.source.bibliographicCitationKoirala KD, Thanh DP, Thapa SD, Arjyal A, Karkey A, Dongol S, et al. Highly resistant Salmonella enterica serovar typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. Antimicrob Agents Chemother. 2012;56(5):2761–2.spa
dc.source.bibliographicCitationChaudhary AS. A review of global initiatives to fight antibiotic resistance and recent antibiotics׳ discovery. Acta Pharm Sin B. 2016;6(6):552–6.spa
dc.source.bibliographicCitationCenter for Disease Dynamics Economics & Policy. The State of the world’s antibiotics 2015. Cent Dis Dyn Econ Policy, CDDEP Washington, DC. 2015;1–84.spa
dc.source.bibliographicCitationEuropean Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). [Internet]. Ecdc. 2014. 1-211 p. Available from: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdfspa
dc.source.bibliographicCitationEuropean Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). [Internet]. Ecdc. 2014. 1-211 p. Available from: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdfspa
dc.source.bibliographicCitationArias CA, Reyes J, Zúñiga M, Cortés L, Cruz C, Rico CL, et al. Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002. J Antimicrob Chemother. 2003;51(1):59–68.spa
dc.source.bibliographicCitationVillegas M V, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect [Internet]. 2008;14 Suppl 1:154–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18154539spa
dc.source.bibliographicCitationGREBO. Manual De Actualizacion En Resistencia Bacteriana Y Normas Clsi M100 – S20. Control [Internet]. 2010;1–78. Available from: http://www.saludcapital.gov.co/sitios/VigilanciaSaludPublica/SiteCollectionDocuments/Manual_Resistencia_SDS_2010.pdfspa
dc.source.bibliographicCitationVallejo M, Cuesta DP, Flórez LE, Correa A, Llanos CE, Isaza B, et al. Características clínicas y microbiológicas de la infección intra-abdominal complicada en Colombia: un estudio multicéntrico. Rev Chil infectología [Internet]. 2016;33(3):261–7. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182016000300002&lng=en&nrm=iso&tlng=enspa
dc.source.bibliographicCitationCohen AL, Calfee D, Fridkin SK, Huang SS, Jernigan JA, Lautenbach E, et al. Recommendations For Metrics For Multidrug-Resistant Organisms In Healthcare Settings: SHEA/HICPAC Position Paper. Infect Control Hosp Epidemiol [Internet]. 2008;29(10):901–13. Available from: https://www.cambridge.org/core/product/identifier/S0195941700049067/type/journal_articlespa
dc.source.bibliographicCitationYoung PY, Khadaroo RG. Surgical site infections. Vol. 94, Surgical Clinics of North America. 2014. p. 1245–64.spa
dc.source.bibliographicCitationSartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. Erratum: The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. [World J Emerg Surg. 12, (2017) (29)] DOI: 10.1186/s13017-017-0141-6. World Journal of Emergency Surgery. 2017.spa
dc.source.bibliographicCitationMorrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals. 2013.spa
dc.source.bibliographicCitationLob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016. Eur J Clin Microbiol Infect Dis. 2018;spa
dc.source.bibliographicCitationSartelli M, Abu-Zidan FM, Catena F, Griffiths EA, Di Saverio S, Coimbra R, et al. Global validation of the WSES Sepsis Severity Score for patients with complicated intra-abdominal infections: A prospective multicentre study (WISS Study). World J Emerg Surg. 2015;spa
dc.source.bibliographicCitationSinapidis D, Kosmas V, Vittoros V, Koutelidakis IM, Pantazi A, Stefos A, et al. Progression into sepsis: An individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis. 2018;spa
dc.source.bibliographicCitationMazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect (Larchmt). 2017;spa
dc.source.bibliographicCitationTakesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, et al. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan. J Infect Chemother. 2018;spa
dc.source.bibliographicCitationTimsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vésin A, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: Study protocol for a randomized controlled trial. Trials. 2013;spa
dc.source.bibliographicCitationGolan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: A systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015;spa
dc.source.bibliographicCitationMartin A, Fahrbach K, Zhao Q, Lodise T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infectious Diseases. 2018.spa
dc.source.bibliographicCitationCenters for Diasease Control and Prevention. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). Natl Cent Emerg Zoonotic Infect Dis. 2014;spa
dc.source.bibliographicCitationKelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. International Journal of Antimicrobial Agents. 2017.spa
dc.source.bibliographicCitationTischendorf J, De Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review. Am J Infect Control. 2016;spa
dc.source.bibliographicCitationEcdc. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. Report. 2015.spa
dc.source.bibliographicCitationWilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, et al. Carbapenem-resistant enterobacter cloacae in patients from the US veterans health administration, 2006–2015. Emerging Infectious Diseases. 2017.spa
dc.source.bibliographicCitationHaidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin Infect Dis. 2017;spa
dc.source.bibliographicCitationLob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;spa
dc.source.bibliographicCitationSantajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Research International. 2016.spa
dc.source.bibliographicCitationCattoir V, Giard JC. Antibiotic resistance in Enterococcus faecium clinical isolates. Expert Review of Anti-Infective Therapy. 2014.spa
dc.source.bibliographicCitationRubinstein E, Keynan Y. Vancomycin-resistant enterococci. Critical Care Clinics. 2013.spa
dc.source.bibliographicCitationMcGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale Journal of Biology and Medicine. 2017.spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectResistenciaspa
dc.subjectMicroorganismospa
dc.subjectInfecciones intraabdominalesspa
dc.subject.ddcEnfermedadesspa
dc.subject.keywordResistancespa
dc.subject.keywordMicroorganismsspa
dc.subject.keywordIntra-abdominal infectionsspa
dc.subject.lembMicrobiología médicaspa
dc.subject.lembInfeccionesspa
dc.subject.lembMicroorganismosspa
dc.titleMicroorganismos y perfiles de resistencia en aislamientos de infecciones quirúrgicas intraabdominales en un Hospital de Bogotá – Colombia, 2017 – 2018spa
dc.typemasterThesiseng
dc.type.documentDescriptivo observacional retrospectivospa
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
GuerreroVergel-AlvaroFelipe.pdf
Tamaño:
1.27 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Cirugía General